[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356300-105":59,"doc-detail-356300-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","two-stage-inertial-microfluidics-enrichment-of-activated-t-cells-towards-a-bead-less-chimeric-antigen-receptor-manufacturing-protocol","Two-stage inertial microfluidics enrichment of activated T-cells towards a bead-less chimeric antigen receptor manufacturing protocol","","CAR-T cell therapy drives cancer immunotherapy through high remission rates, yet manufacturing remains costly and complex. A key early step, T-cell enrichment from patient apheresis, is challenged by cellular impurities that reduce ex vivo transduction and subsequent proliferation. Conventional enrichment, including magnetic-bead selection, limits throughput and can affect cell phenotype. A two-stage, bead-less inertial microfluidics approach yields 87% (SD ± 6%) enrichment with 80% (SD ± 30%) recovery, and ovarian-cancer validation achieves 70% (SD ± 10%) purity from 48% (SD ± 6%) starting purity at 64% (SD ± 4%) recovery, without detectable proliferation impact.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/two-stage-inertial-microfluidics-enrichment-of-activated-t-cells-towards-a-bead-less-chimeric-antigen-receptor-manufacturing-protocol/356300/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/two-stage-inertial-microfluidics-enrichment-of-activated-t-cells-towards-a-bead-less-chimeric-antigen-receptor-manufacturing-protocol/356300.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is T-cell enrichment a critical step in CAR-T manufacturing?","Question",{"text":112,"@type":113},"Enriched T-cells from patient apheresis starting material are required for effective ex vivo transduction and proliferation. Impurities in the initial material interfere with these downstream manufacturing steps.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitations are associated with magnetic bead-based T-cell enrichment?",{"text":117,"@type":113},"Magnetic bead selection can modify T-cell phenotype and activation levels, offers limited throughput and recovery, and requires additional bead removal steps.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the proposed two-stage inertial microfluidics method perform in enrichment and recovery?",{"text":121,"@type":113},"The bead-less dual-stage process reports 87% (SD ± 6%) enrichment and 80% (SD ± 30%) recovery using apheresis-like samples, and ovarian-cancer validation shows improved purity (70% SD ± 10%) from 48% SD ± 6% with 64% (SD ± 4%) T-cell recovery.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356300,1790371497,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Medical Oncology (2026) 43:126  \n[https://doi.org/10.1007/s12032-026-03276-9](https://doi.org/10.1007/s12032-026-03276-9)  \nORIGINAL PAPER  \nTwo-stage inertial microfluidics enrichment of activated T-cells  \ntowards a bead-less chimeric antigen receptor manufacturing protocol  \nMonaT. Elsemary1 · Michelle F. Maritz1 · Louise E. Smith1 · Majid EbrahimiWarkiani2 · Benjamin Thierry1,3  \nReceived: 7 September 2025 / Accepted: 21 January 2026 / Published online: 29 January 2026 © The Author(s) 2026  \nAbstract  \nCAR-T cell therapy is leading the way in the field of cancer cell immunotherapies due to its high success rates. However, the manufacturing of CAR-T cells remains complex and expensive. T-cell enrichment from patient apheresis starting material is a key step in the manufacture but cellular impurities interfere with the ex vivo transduction of T-cells and their proliferation. Current enrichment methods including magnetic bead selection suffer from various limitations. We report here a bead-less T-cell enrichment process through a two-stage procedure based on inertial microfluidics. Using apheresis like starting material samples from healthy donors, the dual-stage process showed an efficient 87%(SD ± 6%) enrichment and 80%(SD ± 30%) recovery of T-cells. Validation of the process with ovarian cancer samples resulted in a T-cell purity 70%(SD ± 10%) from a starting purity of 48%(SD ± 6%) at a 64%(SD ± 4%) T-cell recovery. The two-stage inertial microfluidic process was also shown to have no detectable effect on the proliferation of the cells.  \nKeywords Immunotherapy · Chimeric antigen receptor · Microfluidics · Ovarian cancer · T-cells  \nIntroduction  \nChimeric Antigen Receptor (CAR) T-cell therapy is a form of adoptive cell therapy where a patient’s T-cells are genetically modified to express a cancer specific chimeric antigen receptor and then expanded ex vivo to produce the required dose for therapy. The treatment has yielded remarkably high remission rates in various types of blood cancer [1, 2] . These impressive clinical outcomes led to the approval of six CAR-T drugs to date and driven intense research in both academic and commercial settings aimed at developing new CAR-T cells and/or identifying new targets for the CARs. However, many of the well-known bottlenecks associated to the manufacturing of CAR-T products have yet to be satisfactorily addressed. CAR-T cell manufacturing  \n􀀍 Benjamin Thierry [benjamin.thierry@unisa.edu.au](benjamin.thierry@unisa.edu.au)  \n1 Future Industries Institute, University of South Australia Mawson Lakes Campus, Mawson Lakes, SA 5095, Australia  \n2 School of Biomedical Engineering, University of Technology Sydney, 2007 Broadway, Ultimo, NSW, Australia  \n3 Future Industries Institute, Building X, GPO Box 2471, Mawson Lakes, Adelaide, SA 5001, Australia  \nhas evolved since the early attempts in from investigatorled clinical protocols to centralized manufacturing facilities [3–5] . Conversely, to address the significant logistical challenges of current highly centralized manufacturing, thereis a growing shift toward point-of-care manufacturing [6, 7] . This requires developing innovative methodologies that enable decentralization and automation, while ensuring the  \nquality and reproducibility of CAR T products [8–11] .  \nIn its current autologous format, CAR-T cell therapy relies on a patient own T-cells that are enriched at the start of the manufacturing process. Significant variation in the composition of the initial apheresis product in regard to the amount ofT-cells and their purity is now well documented, which is a major obstacle to standardization of the manufacturing process and occasionally even lead to manufacture failure [12] . Specifically, the T-cells percentages in apheresis products range anywhere from 10% to 90% depending on the patient’s state, type of cancer, cancer stage and prior treatments. Several methods to enrich either the lymphocyte fraction or T-cells have been dev","cbCaim3lsLYVtOYG","https://ap.wps.com/l/cbCaim3lsLYVtOYG","pdf",2523119,15,"English","# Abstract\n# Introduction\n## CAR-T manufacturing bottlenecks\n## T-cell enrichment methods and limitations\n## Microfluidic inertial fractionation principles\n## Prior microfluidic work in CAR-T workflows","[{\"question\":\"Why is T-cell enrichment a critical step in CAR-T manufacturing?\",\"answer\":\"Enriched T-cells from patient apheresis starting material are required for effective ex vivo transduction and proliferation. Impurities in the initial material interfere with these downstream manufacturing steps.\"},{\"question\":\"What limitations are associated with magnetic bead-based T-cell enrichment?\",\"answer\":\"Magnetic bead selection can modify T-cell phenotype and activation levels, offers limited throughput and recovery, and requires additional bead removal steps.\"},{\"question\":\"How does the proposed two-stage inertial microfluidics method perform in enrichment and recovery?\",\"answer\":\"The bead-less dual-stage process reports 87% (SD ± 6%) enrichment and 80% (SD ± 30%) recovery using apheresis-like samples, and ovarian-cancer validation shows improved purity (70% SD ± 10%) from 48% SD ± 6% with 64% (SD ± 4%) T-cell recovery.\"}]","Two-stage inertial microfluidics enrichment of activated T-cells towards a bead-less chimeric antigen receptor manufacturing protocol | PDF",1790124489,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e24259ac966d02debda69ca96245cba0.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3429d0d77aff67af6de714e7880654e.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a17b2b687417669f6b26116ddfdb012.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7dc4ef080bf79a899fca7ed4d6650a48.webp",980,1301]